HCW Biologics, Inc. (HCWB)

NASDAQ: HCWB · IEX Real-Time Price · USD
2.22
-0.09 (-3.90%)
At close: Jan 14, 2022 4:00 PM
2.25
0.03 (1.35%)
After-hours:Jan 14, 2022 7:26 PM EST
Market Cap79.32M
Revenue (ttm)4.10M
Net Income (ttm)-9.02M
Shares Out35.73M
EPS (ttm)-0.73
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume54,366
Open2.30
Previous Close2.31
Day's Range2.17 - 2.30
52-Week Range2.12 - 7.78
Betan/a
AnalystsStrong Buy
Price Target10.00 (+350.5%)
Earnings DateNov 12, 2021

About HCWB

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead product includes HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical ...

IndustryBiotechnology
IPO DateJul 20, 2021
Employees40
Stock ExchangeNASDAQ
Ticker SymbolHCWB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for HCW Biologics stock is "Strong Buy" and the 12-month stock price forecast is 10.00.

Price Target
$10.00
(350.45% upside)
Analyst Consensus: Strong Buy

News

HCW Biologics to Participate in H.C. Wainwright BioConnect Conference January 10 – 13, 2022

MIRAMAR, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen he...

1 week ago - GlobeNewsWire

HCW Biologics' Founder and CEO Dr. Hing C. Wong Named Weaver H.

Award recognizes extraordinary contributions to the growth of life sciences Award recognizes extraordinary contributions to the growth of life sciences

1 month ago - GlobeNewsWire

HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights

MIRAMAR, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), an innovative biopharmaceutical company focused on discovering and developing novel...

2 months ago - GlobeNewsWire

Good Penny Stocks to Buy Right Now? 3 to Watch in November

Are these penny stocks worth buying right now? The post Good Penny Stocks to Buy Right Now?

Other symbols:GSATXELA
2 months ago - PennyStocks

HCWB Stock: The Big FDA News That Has HCW Biologics Booming Today

HCW Biologics (HCWB) stock is rocketing higher on Thursday thanks to a recent update from the U.S. Food and Drug Administration (FDA). The post HCWB Stock: The Big FDA News That Has HCW Biologics Boomin...

2 months ago - InvestorPlace

HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancre...

Company cleared to proceed with first-in-human clinical trial to evaluate HCW9218, Company's lead product candidate, in refractory, advanced/metastatic pancreatic cancer

2 months ago - GlobeNewsWire

HCW Biologics Announces Appointment of Two New Members to Board of Directors

New Members Add Depth to Board with Experience in Strategic Transactions, Strategy and Commercial Planning, and Governance New Members Add Depth to Board with Experience in Strategic Transactions, Strat...

2 months ago - GlobeNewsWire

Making a Penny Stocks Watchlist? Don't Forget These 3 Small-Caps

Three penny stocks that could be worth watching in the second half of October The post Making a Penny Stocks Watchlist? Don't Forget These 3 Small-Caps appeared first on Penny Stocks to Buy, Picks, News...

Other symbols:CEIGSAT
2 months ago - PennyStocks

HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctiona...

Lead Drug Candidate Engineered Using Tissue FactOr-Based FusIon (TOBI™) Platform

4 months ago - GlobeNewsWire

HCW Biologics' Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein ...

TOBI™ Discovery Platform Creates GMP-Scale Heteromeric Fusion Protein Complexes (HFPCs) That Solve Issues with Multi-Signal Receptor Engagement on Immune Cells

4 months ago - GlobeNewsWire

HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights

MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies t...

5 months ago - GlobeNewsWire

HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering

MIRAMAR, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel i...

5 months ago - GlobeNewsWire

HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering

MIRAMAR, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel i...

5 months ago - GlobeNewsWire